The anti-neprilysin market comprises drugs that inhibits neprilysin enzyme, which is involved in the degradation of natriuretic peptides and other vasoactive peptides. These drugs have applications in the treatment of congestive heart failure and hypertension. Anti-neprilysin drugs help in optimizing natriuretic peptide levels as well as enhancing the actions of bradykinin and substance P, which dilate blood vessels and increase blood flow.
The global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd. BIOPROJET is one of the leading players focusing on developing first-in-class neprilysin inhibitors for indications like heart failure.
The demand for anti-neprilysin drugs is expected to rise significantly during the forecast period due to the increasing prevalence of cardiovascular diseases globally. As per the WHO, cardiovascular diseases are the leading cause of death worldwide, with over 17 million deaths annually. Anti-neprilysin drugs can aid in the treatment of heart failure as well as lower blood pressure levels effectively.
Neprilysin inhibitors are evolving significantly in terms of their applications. Earlier, these drugs were majorly tested for treatment of heart failure. Now, ongoing research and clinical trials are exploring the use of anti-neprilysin drugs in other conditions like delayed graft function post-kidney transplantation and pulmonary fibrosis. New formulations and drug delivery approaches are also being evaluated to enhance patient compliance.
Market Trends
Combination therapies emerging as a key trend – Many drug developers are evaluating the potential of anti-neprilysin inhibitors in combination with other heart failure drugs like angiotensin receptor blockers. Ongoing research aims to enhance treatment efficacy through synergistic drug interactions.
Focus on specialty indications gaining traction – Researchers are investigating the role of neprilysin inhibitors beyond just heart failure management. Conditions like diabetic kidney disease and respiratory diseases are being actively explored. This reflects opportunities in different therapeutic segments.
Market Opportunities
High unmet needs in developing nations – Countries in Asia Pacific, Latin America, and Africa contribute significantly to the global heart failure disease burden. However, diagnosis and treatment access remain major challenges in these areas. This presents lucrative opportunities for affordable anti-neprilysin drugs.
Novel formulations and delivery systems – Transdermal patches, long-acting injectables, and other advanced drug delivery technologies can help address adherence issues with oral therapies. Their development may attract interest from pharma companies.
Impact of COVID-19 on Anti-Neprilysin Market Growth
The COVID-19 pandemic significantly impacted the growth of the anti-neprilysin market. During the initial outbreak, lockdowns imposed worldwide disrupted supply chains and halted production across major manufacturing facilities. Clinical trials involving neprilysin inhibitors were delayed due to restrictions on clinical research activities.
Many patients suffering from heart failure and acute decompensated heart failure avoided hospital visits during this period due to fear of virus exposure. This substantially reduced demand for neprilysin inhibitor drugs in 2020. However, with rising infections putting additional strain on healthcare systems, neprilysin inhibitors emerged as important treatment options for COVID-19 patients with cardiac complications. Some clinical studies even explored using neprilysin inhibitors along with ACE inhibitors for superior management of COVID-19 associated heart damage.
Going forward, the market is expected to witness steady recovery. Manufacturers are ramping up production while ensuring strict safety protocols. Telehealth and home healthcare are enabling continuity of treatment. Regulatory bodies are also expediting approvals of neprilysin inhibitors to expand treatment access. Ongoing research on novel neprilysin inhibitors holds promise to further boost the market in the post pandemic years.
Geographical Regions with High Anti-Neprilysin Market Concentration
North America currently dominates the anti-neprilysin market in terms of value, accounting for over 35% share. This is attributed to growing heart failure prevalence, rising geriatric population, established healthcare infrastructure and high adoption of novel therapeutics. Europe is the second largest regional market supported by favorable government initiatives for cardiac care and research. The Asia Pacific region is anticipated to be the fastest growing market during the forecast period. This growth can be credited to increasing awareness about neprilysin inhibitors, rising healthcare expenditure and expanding base of cardiac patients in highly populated countries like China and India.
Europe is poised to witness the fastest growth in the anti-neprilysin market worldwide. Factors such as evolving unmet needs of cardiac patients, early access to innovative drugs, rising collaborations between market players and research organizations and presence of major clinical research hubs will support the ongoing expansion of the European market. Germany, U.K. and France currently represent substantial revenue opportunities for anti-neprilysin manufacturers. Promising pipeline candidates under development by regional pharma firms also highlight lucrative prospects across Eastern European markets.
